Pharmaceutical Technology21 小时
Central Nervous System Disorders by Neuroplast for Amyotrophic Lateral Sclerosis ...
Central Nervous System Disorders is under clinical development by Neuroplast and currently in Phase I for Amyotrophic Lateral Sclerosis.
Pharmaceutical Technology21 小时
NX-210c by Axoltis Pharma for Parkinson’s Disease: Likelihood of Approval
NX-210c is under development for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis (RRMS), unspecified indication. The drug candidate is ...